BioCentury
ARTICLE | Clinical News

Concentric reports Phase Ib data for non-opioid postsurgical pain candidate

May 14, 2018 8:34 PM UTC

Concentric Analgesics Inc. (San Francisco, Calif.) reported top-line data from a Phase Ib trial to treat postsurgical pain following a bunionectomy showing that the highest dose of a single intraoperative injection of CA-008 led to a significant >50% reduction in pain intensity lasting for up to 168 hours as measured by the area under the curve (AUC) on a numeric rating scale (NRS) compared with placebo. High-dose CA-008 also led a 50% reduction in opioid consumption vs. placebo. Concentric said the trial was not powered for efficacy.

The double-blind, U.S. trial enrolled 40 patients undergoing a bunionectomy with standard of care (SOC) bupivacaine to receive saline control or one of five ascending doses of CA-008 administered via wide infiltration at the surgical site. CA-008 was well tolerated with no serious adverse events or dose-limiting toxicities (DLTs) reported. The company also said CA-008 had no observed effect on wound healing...